EP0716614A4 - Behandlung von menschlichen tumoren durch genetische transformation von menschlichen tumorzellen - Google Patents

Behandlung von menschlichen tumoren durch genetische transformation von menschlichen tumorzellen

Info

Publication number
EP0716614A4
EP0716614A4 EP94926678A EP94926678A EP0716614A4 EP 0716614 A4 EP0716614 A4 EP 0716614A4 EP 94926678 A EP94926678 A EP 94926678A EP 94926678 A EP94926678 A EP 94926678A EP 0716614 A4 EP0716614 A4 EP 0716614A4
Authority
EP
European Patent Office
Prior art keywords
human
treatment
tumor cells
genetic transformation
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94926678A
Other languages
English (en)
French (fr)
Other versions
EP0716614A1 (de
Inventor
Edward J Oldfield
Zvi Ram
R Michael Blaese
Kenneth W Culver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP0716614A1 publication Critical patent/EP0716614A1/de
Publication of EP0716614A4 publication Critical patent/EP0716614A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
EP94926678A 1993-09-03 1994-09-02 Behandlung von menschlichen tumoren durch genetische transformation von menschlichen tumorzellen Withdrawn EP0716614A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11666993A 1993-09-03 1993-09-03
US116669 1993-09-03
PCT/US1994/009961 WO1995006486A1 (en) 1993-09-03 1994-09-02 Treatment of human tumors by genetic transformation of human tumor cells

Publications (2)

Publication Number Publication Date
EP0716614A1 EP0716614A1 (de) 1996-06-19
EP0716614A4 true EP0716614A4 (de) 1998-02-04

Family

ID=22368537

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94926678A Withdrawn EP0716614A4 (de) 1993-09-03 1994-09-02 Behandlung von menschlichen tumoren durch genetische transformation von menschlichen tumorzellen

Country Status (4)

Country Link
EP (1) EP0716614A4 (de)
JP (1) JPH09505557A (de)
CA (1) CA2169557A1 (de)
WO (1) WO1995006486A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537541B1 (en) 1990-09-14 2003-03-25 The General Hospital Corporation Implantation of HSV-TK retrovirus producer cells to destroy glioma
US6555108B1 (en) 1990-09-14 2003-04-29 The General Hospital Corporation Implanting HSV-TK retrovirus producing cells to treat tumors
AU2434195A (en) * 1994-05-02 1995-11-29 University Of Washington Thymidine kinase mutants
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US6207648B1 (en) 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
GB9801902D0 (en) * 1998-01-29 1998-03-25 Cancer Res Campaign Tech A gene promoter
EP1153136A2 (de) 1998-12-09 2001-11-14 The General Hospital Corporation Verbessertes verpacken von hsv-amplikons und herstellung von rekombinanten viralen vektoren
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
US6770632B1 (en) 1999-07-16 2004-08-03 The General Hospital Corporation Folypolyglutamyl synthetase gene transfer to enhance antifolate
US7214515B2 (en) 2001-01-05 2007-05-08 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic DNA inserts
EP3777980B1 (de) 2013-10-29 2023-12-06 President and Fellows of Harvard College Nuclear factor erythroid 2-like 2 (nrf2) zur verwendung in der behandlung der altersbedingten makuladegeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4583538A (en) * 1984-05-04 1986-04-22 Onik Gary M Method and apparatus for stereotaxic placement of probes in the body utilizing CT scanner localization
US4813399A (en) * 1986-07-18 1989-03-21 Gordon Robert T Process for the treatment of neurological or neuromuscular diseases and development
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BRAIN NERVE (TOKYO), vol. 38, no. 6, 1986, pages 593 - 598 *
CULVER ET AL: "IN VIVO GENE TRANSFER WITH RETROVIRAL VECTOR-PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN TUMORS", SCIENCE, vol. 256, 1992, pages 1550 - 1552, XP002045618 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; OKAMOTO ET AL: "CLINICAL STUDIES OF ADOPTIVE IMMUNOTHERAPY OF HUMAN DISSEMINATED BRAIN TUMORS WITH LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN 2", XP002045621 *
DATABASE MEDLINE FILE SERVER STN KARLSRUHE; PLUNKETT ET AL: "STEROTAXIC IMPLANTATION OF DISPERSED CELL SUSPENSIONS INTO BRAIN. A SYSTEMATIC APPRAISAL OF CELL PLACEMENT AND SURVIVAL", XP002045622 *
GILBERT ET AL: "CELL TRANSPLANTATION OF GENETICALLY ALTERED CELLS ON BIODEGRADABLE POLYMER SCAFFOLDS IN SYNGENEIC RATS", TRANSPLANTATION, vol. 56, August 1993 (1993-08-01), pages 423 - 427, XP002045620 *
JOURNAL OF NEUROSURGERY, vol. 69, no. 2, 1988, pages 228 - 233 *
RAM ET AL: "IN SITU RETROVIRAL-MEDIATED GENE TRANSFER FOR THE TREATMENT OF BRAIN TUMORS IN RATS", CANCER RESEARCH, vol. 53, 1 January 1993 (1993-01-01), pages 83 - 88, XP002045617 *
See also references of WO9506486A1 *
SHORT ET AL: "GENE DELIVERY TO GLIOMA CELLS IN RAT BRAIN BY GRAFTING OF A RETROVIRUS PACKAGING CELL LINE", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 27, 1990, pages 427 - 433, XP002045619 *

Also Published As

Publication number Publication date
JPH09505557A (ja) 1997-06-03
WO1995006486A1 (en) 1995-03-09
EP0716614A1 (de) 1996-06-19
CA2169557A1 (en) 1995-03-09

Similar Documents

Publication Publication Date Title
DK0839154T3 (da) Biologiske aktive peptider og præparater samt anvendelse deraf
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
FI943625L (fi) Menetelmiä tulehduksellisten ihotautien hoitamiseksi
EP0716614A4 (de) Behandlung von menschlichen tumoren durch genetische transformation von menschlichen tumorzellen
DE69631423D1 (de) Chinolone und deren therapeutische verwendung
ATE364614T1 (de) Tumornekrose-faktor-gamma
BR9707425A (pt) Composto processo terapêutico para inibir o crescimento de células cancerosas e processo para utilizar o composto
NZ269653A (en) Treatment of protein kinase c-related diseases by gene therapy
BR9408407A (pt) Uso de inibidores pla2 como tratamento para doença de alzheimer
FI973827L (fi) Biologisen kudoksen stimulointi optisella energialla
EP0636025A4 (en) Compounds useful for treating allergic or inflammatory diseases.
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
FI900808A0 (fi) Humant mannos bindande protein.
FI953423A0 (fi) Temotsolomidin tehostaminen ihmisten kasvainsoluissa
FI883487L (fi) Ihmisen kudostekijäinhibiittorin DNA-klooni
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
EP0772625A4 (de) Oligonukleoside und verfahren zur hemmung des tumorwachstums, der invasion und der metastasenbildung
EP1539197A4 (de) Behandlung von tumorzellen zur verwendung in der immuntherapie bei krebs
EP0591408A4 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
EP0722343A4 (de) Die behandlung von tumoren durch genetische transformation von tumorzellen mit genen, die für selektive, negative marker und für cytokine kodieren
IT8720181A0 (it) Composizioni farmaceutiche contenenti alcoli superiori per il trattamento di patologie della prostata.
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19971218

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000403